This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
HAYES, Inc.. Comparative effectiveness of bupivacaine liposome injectable suspension for relief of postoperative pain following joint arthroplasties
. Lansdale: HAYES, Inc.. Directory Publication. 2016
Liposomal bupivacaine (LB) is a drug delivery formulation in which the local anesthetic bupivacaine hydrochloride is encapsulated within multivesicular liposomes to provide slow, sustained release of bupivacaine for postoperative pain relief after single-dose, localized administration.
Rationale: Bupivacaine hydrochloride (HCl) analgesia is commonly used in patients undergoing total joint arthroplasty (TJA). LB uses a liposomal delivery technology to prolong bupivacaine's analgesic effect during the first few days after surgery, potentially reducing the need for opioids and other pain medications, and possibly facilitating inpatient rehabilitation.
Relevant Questions: How does LB compare with other forms of analgesia for reducing pain and opioid consumption following TJA (i.e., total hip arthroplasty, total knee arthroplasty, and total shoulder arthroplasty)? How does LB compare with other forms of analgesia for with respect to function and rehabilitation outcomes, hospital length of stay, and patient satisfaction following TJA? How does LB compare with other types of analgesia with respect to safety in patients undergoing TJA? Have definitive patient selection criteria for LB been established?
Subject indexing assigned by CRD
Arthroplasty; Bupivacaine; Humans; Liposomes; Pain, Postoperative
Country of organisation
An English language summary is available.
Address for correspondence
HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: email@example.com
Date abstract record published